SAPPHIRE Aurora-GT™ eNOS Gene Therapy

DRUG/DEVICE
Autologous endothelial progenitor cells transfected with human endothelial nitric oxide synthase, for intravenous use
ROUTE OF ADMINISTRATION
Intravenous
THERAPEUTIC PLATFORM
NCE / Novel Biologics
CLINICAL TRIAL
TERRITORY
Canadian Study; United States license
STATUS
Registration phase study in Canada
Aurora-GT™ is a development-stage product not approved for sale in any jurisdiction.